Cubist Systematic Strategies LLC Has $1.98 Million Holdings in Immatics (NASDAQ:IMTX)

Cubist Systematic Strategies LLC raised its holdings in Immatics (NASDAQ:IMTX) by 686.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 278,382 shares of the company’s stock after buying an additional 242,988 shares during the quarter. Cubist Systematic Strategies LLC owned 0.23% of Immatics worth $1,979,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in IMTX. abrdn plc lifted its stake in Immatics by 49.2% in the fourth quarter. abrdn plc now owns 347,379 shares of the company’s stock valued at $2,470,000 after buying an additional 114,479 shares during the period. Y Intercept Hong Kong Ltd bought a new position in shares of Immatics during the 4th quarter worth about $211,000. Platinum Investment Management Ltd. boosted its position in shares of Immatics by 53.1% during the 4th quarter. Platinum Investment Management Ltd. now owns 311,722 shares of the company’s stock worth $2,216,000 after purchasing an additional 108,108 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Immatics by 24.6% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company’s stock worth $163,000 after purchasing an additional 4,477 shares in the last quarter. Finally, Schroder Investment Management Group boosted its position in shares of Immatics by 52.6% during the 4th quarter. Schroder Investment Management Group now owns 427,994 shares of the company’s stock worth $2,953,000 after purchasing an additional 147,547 shares in the last quarter. 64.41% of the stock is owned by institutional investors and hedge funds.

Immatics Trading Down 2.3%

NASDAQ IMTX opened at $4.24 on Monday. The company has a fifty day simple moving average of $4.48 and a 200 day simple moving average of $5.98. Immatics has a 12-month low of $3.30 and a 12-month high of $13.77. The company has a market cap of $515.37 million, a P/E ratio of -6.42 and a beta of 0.87.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings results on Thursday, March 27th. The company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.51. The business had revenue of $15.67 million during the quarter, compared to the consensus estimate of $16.16 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. Sell-side analysts predict that Immatics will post -0.72 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Immatics in a research report on Tuesday, April 1st. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $16.67.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.